Notice of Allowability	Application No.	Applicant(s)
	09/463,542	AUWERX ET AL.
	Examiner	Art Unit
	Maria B. Marvich, PhD	1633
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>an after final amendment 1/12/06</u> .		
2. The allowed claim(s) is/are <u>9-11,18 and 26-33</u> .		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 		
Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892)	5. ☐ Notice of Informal Pa	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Date	(PTO-413),
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date	3), 7. ⊠ Examiner's Amendm	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Stateme	nt of Reasons for Allowance
-	9.	
		`

ALLOWANCE

This office action is in response to an after-final amendment filed 1/12/06. The amendment has been entered. Claims 1-8, 12-17, 19-25 and 34-41 have been cancelled. Claims 9-11, 18, 27, 28, 31 and 33 have been amended.

Claims 9-11, 18 and 26-33 are pending in this application.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Stephanie Seidman on February 16, 2006.

Claim 9 (amended): An isolated[[,]] or purified or enriched recombinant nucleic acid molecule, comprising a control region of a human peroxisome proliferators activated receptor gamma (PPARγ) gene, wherein the control region comprises nucleotides 1-125 of SEQ ID NO:1.

Claim 10 (amended): An isolated[[,]] or purified or enriched recombinant nucleic acid molecule, comprising a control region of a human peroxisome proliferators activated receptor gamma (PPARy) gene, wherein the control region comprises nucleotides 818-1320 of SEQ ID NO:3.

Art Unit: 1633

Claim 11 (amended): An isolated[[,]] or purified or enriched_recombinant nucleic acid molecule, comprising a control region of a human peroxisome proliferators activated receptor gamma (PPARy) gene, wherein the control region comprises nucleotides 368-1144 of SEQ ID NO:34.

In claim 18, line 1, the word -- isolated-- has been inserted prior to the phrase "cell, comprising".

In claim 28, line 1, the word -- isolated-- has been inserted prior to the phrase "cell, comprising".

In claim 31, line 1, the word -- isolated-- has been inserted prior to the phrase "cell, comprising".

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maria B. Marvich, PhD whose telephone number is (571)-272-0774. The examiner can normally be reached on M-F (6:30-3:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Nguyen, PhD can be reached on (571)-272-0731. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/463,542

Art Unit: 1633

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Maria B Marvich, PhD

Page 4

Examiner

Art Unit 1633

February 16, 2006

DAVETRONG NGUYEN
SUPERVISORY PATENT EXAMINER